1/23
05:06 am
atxs
Astria Therapeutics (NASDAQ:ATXS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Astria Therapeutics (NASDAQ:ATXS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
04:00 pm
atxs
Astria Stockholders Vote to Approve Acquisition by BioCryst
Low
Report
Astria Stockholders Vote to Approve Acquisition by BioCryst